Table 2.
Liver transplantation for HCC patients with PVTT.
| Author, Year | Country | Study design | N (Enrollment Period) | Treatment | Downstaging before LT | Classification of PVTT (n) | Survival time | DFS rate(1-,3-,5-year) | OS rate(1-,3-,5-year) |
|---|---|---|---|---|---|---|---|---|---|
| Yang, 2020 (112) | China | Retrospective study | 75 (2016-2018) | DDLT | NA | Vp2-3 (47) | NA | 44.4%,40.0%, NA | 74.1%, 65.4%, NA |
| Vp4 (28) | NA | 28.6%,21.4%, NA | 64.3%, 30.6%, NA | ||||||
| Assalino, 2020 (113) | Switzerland | Retrospective study | 30 (2004-2018) | DDLT/LDLT | Yes | Vp1 (7); Vp2 (12); Vp3 (5); Hepatic vein (6) | NA | 63.3%, 56.3%, 56.3% | 76.7%, 66.2%, 59.6% |
| Soin, 2020 (114) | India | Prospective study | 46 (2006-2017) | LDLT | Yes | Vp1 (1); Vp2 (12); Vp3 (11); Vp4 (1) | NA | 77%, 77%, 51% | 82%, 57%, 57% |
| No | Vp1 (5); Vp2 (13); Vp3 (3); Vp4 (0) | NA | 63%, 48%, 40% | 80%, 59%, 48% | |||||
| Jeng, 2018 (115) | China | Case report | 1 (2013) | DDLT | Yes | Type II | DFS is more than 20 months | NA | NA |
| Levi, 2017 (116) | Italy | Case series | 4 (2002-2015) | DDLT | Yes | Vp1 (3); Vp3 (1) | Median DFS: 39.1 (6–76) months | NA | NA |
| Lee, 2017 (117) | Korea | Retrospective study | 11 (2009-2013) | LDLT | Yes | Vp3 (3); Vp4 (1) | Mean DFS: 8.3 (1-20) months | 63.6%, 45.5%, 45.5% | 72.7%, 63.6%, 63.6% |
| No | Vp2 (3); Vp3 (1); Vp4 (3) | ||||||||
| Jeong, 2017 (118) | Korea | Retrospective study | 17 (2007-2014) | LDLT | Yes | Vp2 (7); Vp3 (7); Vp4 (1); Hepatic vein (2) | NA | 70.6%, 57.8%, NA | 87.45%, 60.5%, NA |
| Choi, 2017 (119) | Korea | Retrospective study | 34 (2005-2015) | LDLT | NA | Type I (27) | NA | 68.2%, 63.9%, 63.9% | 85%, 60.3%, 50.3% |
| Type II (7) | NA | 28.6%, 14.3%, 14.3% | 71.4%, 14.3%, 14.3% | ||||||
| Han, 2016 (120) | Korea | Retrospective study | 8 (2011-2012) | LDLT | Yes | Type II, Type III | MST: 33 (22–48) months | 87.5%, NA, NA | NA |
| Ettorre, 2010 (121) | Italy | Case report | 1 (2009) | DDLT | Yes | Type II | survival for more than 4 years | NA | NA |
| Zhou, 2011 (122) | China | Retrospective study | 12 (2003-2010) | DDLT | No | Type II (6); Type III (6) | MST: 7 months | NA | 30.0%, 10.0%, NA |
| Wang, 2010 (123) | China | Retrospective study | 62 (2001-2007) | DDLT | NA | Type I0 (12); Type I-III (50) | NA | 29.6%, 13.4%, NA | NA |
| Xu, 2004 (124) | China | Retrospective study | 24 (1999-2003) | DDLT | NA | Type II (14); Type III (10) | MST: 8 months | 29.5%, NA, NA | 23.2%, NA, NA |
PVTT, portal vein tumor thrombus; DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; MST, median survival time; DFS, disease free survival; OS, overall survival; NA, not available.